Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-3505 vs Crizotinib in Treatment-Naive ALK-Positive NSCLC
NCT06254599Phase 3Not yet recruiting
- Sponsor
- Shouyao Holdings
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ficonalkib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shouyao Holdings. Primary endpoint: Progression-Free Survival up to 2 years. Planned start May 2024; status: not yet recruiting.
02
Drugs
ficonalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06254599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254599.